ARCHIVE SEARCH
      -OR-  
 
  NEWS CHANNELS
Fitness News
Asthma Allergy News
 > Diabetes News
Women's Health News
Men's Health News

  MY NEWS
Personal Archive
My Account

  ABOUT THIS NEWSFEED
About Us
Advertise With Us
Feed Your Site
Contact Us


Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

 
ESC: DPP-4 Inhibitors Don't Reduce Cardio Risk in T2DM
Two studies demonstrate no difference versus placebo for saxagliptin, alogliptin

TUESDAY, Sept. 3 (HealthDay News) -- For patients with type 2 diabetes, treatment with the dipeptidyl peptidase 4 (DPP-4) inhibitors saxagliptin or alogliptin is not associated with improvements in cardiovascular risk, according to two studies published online Sept. 2 in the New England Journal of Medicine to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 31 to Sept. 4 in Amsterdam.

Benjamin M. Scirica, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues randomized 16,492 patients with type 2 diabetes with a history of, or at risk for, cardiovascular events to receive saxagliptin or placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. During a median follow-up of 2.1 years, the researchers found that the primary end point event occurred in 7.3 percent of participants in the saxagliptin group and 7.2 percent of participants in the placebo group.

William B. White, M.D., from the University of Connecticut School of Medicine in Farmington, and colleagues randomized 5,380 patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The researchers found that the primary end point occurred in 11.3 percent of patients assigned to alogliptin and 11.8 percent assigned to placebo.

"In conclusion, among patients with type 2 diabetes and a recent acute coronary syndrome, treatment with alogliptin resulted in rates of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke that were similar to those with placebo," White and colleagues write.

The Scirica study was funded by AstraZeneca and Bristol-Myers Squibb. The White study was funded by Takeda Development.

Full Text - Scirica
Full Text - White
Perspective
More Information



Copyright © 2013 HealthDay. All rights reserved.


Back to Top Stories
  GOOGLE ADS